| Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 IE Wertz, S Kusam, C Lam, T Okamoto, W Sandoval, DJ Anderson, ... Nature 471 (7336), 110-114, 2011 | 870 | 2011 |
| Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects AR Johnson, AG Pavlovsky, DF Ortwine, F Prior, CF Man, DA Bornemeier, ... Journal of Biological Chemistry 282 (38), 27781-27791, 2007 | 250 | 2007 |
| Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity CA Dendrou, A Cortes, L Shipman, HG Evans, KE Attfield, L Jostins, ... Science translational medicine 8 (363), 363ra149-363ra149, 2016 | 242 | 2016 |
| Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development JJ Crawford, AR Johnson, DL Misner, LD Belmont, G Castanedo, R Choy, ... Journal of medicinal chemistry 61 (6), 2227-2245, 2018 | 226 | 2018 |
| Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition PJ Lupardus, M Ultsch, H Wallweber, P Bir Kohli, AR Johnson, ... Proceedings of the National Academy of Sciences 111 (22), 8025-8030, 2014 | 205 | 2014 |
| Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations AR Johnson, PB Kohli, A Katewa, E Gogol, LD Belmont, R Choy, ... ACS chemical biology 11 (10), 2897-2907, 2016 | 147 | 2016 |
| Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain Y Wang, AR Johnson, QZ Ye, RD Dyer Journal of Biological Chemistry 274 (46), 33043-33049, 1999 | 131 | 1999 |
| A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors SJ Sohn, K Barrett, A Van Abbema, C Chang, PB Kohli, H Kanda, J Smith, ... The Journal of Immunology 191 (5), 2205-2216, 2013 | 125 | 2013 |
| NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus HD Brightbill, E Suto, N Blaquiere, N Ramamoorthi, S Sujatha-Bhaskar, ... Nature communications 9 (1), 179, 2018 | 115 | 2018 |
| RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases S Patel, JD Webster, E Varfolomeev, YC Kwon, JH Cheng, J Zhang, ... Cell Death & Differentiation 27 (1), 161-175, 2020 | 112 | 2020 |
| Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors JJ Kulagowski, W Blair, RJ Bull, C Chang, G Deshmukh, HJ Dyke, ... Journal of Medicinal Chemistry 55 (12), 5901-5921, 2012 | 107 | 2012 |
| Lead identification of novel and selective TYK2 inhibitors J Liang, V Tsui, A Van Abbema, L Bao, K Barrett, M Beresini, ... European journal of medicinal chemistry 67, 175-187, 2013 | 106 | 2013 |
| A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition LL Johnson, AG Pavlovsky, AR Johnson, JA Janowicz, CF Man, ... Journal of Biological Chemistry 275 (15), 11026-11033, 2000 | 98 | 2000 |
| Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors J Liang, A van Abbema, M Balazs, K Barrett, L Berezhkovsky, W Blair, ... Journal of medicinal chemistry 56 (11), 4521-4536, 2013 | 92 | 2013 |
| Quinazolinones and Pyrido[3,4-d]pyrimidin-4-ones as Orally Active and Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis JJ Li, J Nahra, AR Johnson, A Bunker, P O’Brien, WS Yue, DF Ortwine, ... Journal of medicinal chemistry 51 (4), 835-841, 2008 | 92 | 2008 |
| Minor structural change to tertiary sulfonamide RORc ligands led to opposite mechanisms of action O René, BP Fauber, GL Boenig, B Burton, C Eidenschenk, C Everett, ... ACS medicinal chemistry letters 6 (3), 276-281, 2015 | 81 | 2015 |
| Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2 M Zak, CA Hurley, SI Ward, P Bergeron, K Barrett, M Balazs, WS Blair, ... Journal of medicinal chemistry 56 (11), 4764-4785, 2013 | 81 | 2013 |
| A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis A Johnson, F Lermioglu, UC Garg, R Morgan-Boyd, A Hassid Biochemical and biophysical research communications 152 (2), 893-897, 1988 | 76 | 1988 |
| Discovery of imidazo [1, 5-a] pyridines and-pyrimidines as potent and selective RORc inverse agonists BP Fauber, A Gobbi, K Robarge, A Zhou, A Barnard, J Cao, Y Deng, ... Bioorganic & Medicinal Chemistry Letters 25 (15), 2907-2912, 2015 | 74 | 2015 |
| Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL SD Reiff, EM Muhowski, D Guinn, A Lehman, CA Fabian, C Cheney, ... Blood, The Journal of the American Society of Hematology 132 (10), 1039-1049, 2018 | 72 | 2018 |
Ben FauberDell Technologies在 dell.com 的电子邮件经过验证
